Dr Drew Brockman
Head of Toxicology
Dr Brockman has gained considerable experience in the field of preclinical toxicology in his role at TetraQ during the past seven years. He currently designs and conducts preclinical rodent pharmacokinetic, toxicology, and efficacy studies for external commercial entities, as well as collaborators within the University sector, for submission to regulatory authorities. He has lead projects as a postdoctoral researcher at the University of Minnesota in the US and at the University of Queensland in Australia ranging from determining the molecular mechanisms of treatments for chronic diseases to preclinical pharmacology and toxicology for drug discovery. Dr Brockman has a strong interest in helping the biotech industry bring small molecules and biologics, particularly vaccines, through to clinical trials.